Dose-dependent elevation of intracellular ROS by CPS45 is cell specific and shows preferential targeting of cells in S phase. (A) Comparison of dose-dependent killing of the mouse L1210 leukemia cell line by CPS45 and thalidomide. (B) Profile of cell and dose-dependent elevation of intracellular ROS (DCFDA fluorescence) in Jurkat, L1210, and HeLa cells treated with increasing concentrations of CPS45 (1 nM-10 μM) or thalidomide (1 nM-200 μM). (C) L1210 cells synchronized in G1, S, and G2 phases of the cell cycle by centrifugal elutriation (top panel) were treated with increasing doses of CPS45 (1 nM-10 μM) for 16 hours. Viability of cells at each stage of the cell cycle was determined by MTT assay (bottom panel). Shown are the results of 2 independent experiments. Error bars represent SEM.
